Leveraging transcriptomic, DNA methylation, and molecular alteration data to optimize the classification of IDH-mutant gliomas for therapy selection

L. Nicolas Gonzalez Castro

Open source

DOI
10.3389/fonc.2025.1674987
Published
2026-01-12
Container
Frontiers in Oncology
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2025.1674987,
  title = {Leveraging transcriptomic, DNA methylation, and molecular alteration data to optimize the classification of IDH-mutant gliomas for therapy selection},
  author = {L. Nicolas Gonzalez Castro},
  year = {2026},
  journal = {Frontiers in Oncology},
  doi = {10.3389/fonc.2025.1674987},
  url = {https://doi.org/10.3389/fonc.2025.1674987}
}

RIS

TY  - JOUR
TI  - Leveraging transcriptomic, DNA methylation, and molecular alteration data to optimize the classification of IDH-mutant gliomas for therapy selection
AU  - L. Nicolas Gonzalez Castro
PY  - 2026
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2025.1674987
UR  - https://doi.org/10.3389/fonc.2025.1674987
ER  - 

APA

Castro, L. N. G. (2026). Leveraging transcriptomic, DNA methylation, and molecular alteration data to optimize the classification of IDH-mutant gliomas for therapy selection. Frontiers in Oncology. https://doi.org/10.3389/fonc.2025.1674987

Source records